abstract |
The present invention relates to compounds that act as potent antagonists of the CCR1 receptor and have anti-inflammatory activity in vivo. The compounds of the present invention are generally aryl piperazine derivatives, and are useful as controls in pharmaceutical compositions, methods of treatment of CCR1-mediated diseases, and assays to identify competitive CCR1 antagonists. |